Exelixis Inc. (EXEL)

20.63
NASDAQ : Health Technology
Prev Close 20.63
Day Low/High 0.00 / 0.00
52 Wk Low/High 18.50 / 32.50
Avg Volume 3.50M
Exchange NASDAQ
Shares Outstanding 296.87M
Market Cap 5.89B
EPS 0.50
P/E Ratio 24.48
Div & Yield N.A. (N.A)

Latest News

Who Are the Trade War Victims?: Cramer's 'Mad Money' Recap (Tues. 6/19/18)

Who Are the Trade War Victims?: Cramer's 'Mad Money' Recap (Tues. 6/19/18)

Jim Cramer says the U.S. has the upper hand when it comes to the tariffs because we import far more from China than they import from us.

Exelixis To Present At The William Blair & Co. 38th Annual Growth Stock Conference On June 12, 2018

Exelixis To Present At The William Blair & Co. 38th Annual Growth Stock Conference On June 12, 2018

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Exelixis Announces Results From Sub-Group Analyses Of The Phase 3 Pivotal CELESTIAL Trial Of Cabozantinib For Advanced Hepatocellular Carcinoma Presented At ASCO 2018

Exelixis Announces Results From Sub-Group Analyses Of The Phase 3 Pivotal CELESTIAL Trial Of Cabozantinib For Advanced Hepatocellular Carcinoma Presented At ASCO 2018

Exelixis, Inc. (Nasdaq: EXEL) today announced results from sub-group analyses of the CELESTIAL phase 3 pivotal trial of cabozantinib in advanced hepatocellular carcinoma (HCC) comparing outcomes by duration of sorafenib treatment in patients whose only...

Exelixis Announces Further Expansion To Clinical Research Protocol For Phase 1b COSMIC-021 Trial Of Cabozantinib In Combination With Anti-PD-L1 Immunotherapy In Patients With Locally Advanced Or Metastatic Solid Tumors

Exelixis Announces Further Expansion To Clinical Research Protocol For Phase 1b COSMIC-021 Trial Of Cabozantinib In Combination With Anti-PD-L1 Immunotherapy In Patients With Locally Advanced Or Metastatic Solid Tumors

Exelixis, Inc. (Nasdaq:EXEL) today announced an amendment to the protocol for COSMIC-021, the phase 1b trial of cabozantinib (CABOMETYX ®) in combination with atezolizumab (TECENTRIQ ®) in patients with locally advanced or metastatic solid tumors to add...

Exelixis Appoints Andrew R. Peters To Newly Created Position Of Vice President, Strategy

Exelixis Appoints Andrew R. Peters To Newly Created Position Of Vice President, Strategy

Exelixis, Inc. (NASDAQ: EXEL) today announced the appointment of Andrew R.

Exelixis' Partner Ipsen Announces European Commission Approval Of CABOMETYX® (Cabozantinib) For Previously Untreated Intermediate- Or Poor-Risk Advanced Renal Cell Carcinoma

Exelixis' Partner Ipsen Announces European Commission Approval Of CABOMETYX® (Cabozantinib) For Previously Untreated Intermediate- Or Poor-Risk Advanced Renal Cell Carcinoma

Exelixis, Inc. (Nasdaq:EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX ® (cabozantinib) 20 mg, 40 mg and 60 mg for the first-line treatment of adults with intermediate- or poor-risk advanced...

Exelixis Provides Update On IMblaze370 Phase 3 Pivotal Trial Of Atezolizumab And Cobimetinib In Patients With Heavily Pretreated Locally Advanced Or Metastatic Colorectal Cancer

Exelixis Provides Update On IMblaze370 Phase 3 Pivotal Trial Of Atezolizumab And Cobimetinib In Patients With Heavily Pretreated Locally Advanced Or Metastatic Colorectal Cancer

Exelixis, Inc. (Nasdaq:EXEL) today announced that IMblaze370, the phase 3 pivotal trial of atezolizumab (TECENTRIQ ®), an anti-PDL1 antibody discovered and developed by Genentech, a member of the Roche Group, and cobimetinib (COTELLIC ®), an...

Exelixis To Present At The Bank Of America Merrill Lynch Health Care Conference On May 15, 2018

Exelixis To Present At The Bank Of America Merrill Lynch Health Care Conference On May 15, 2018

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Two Oncology Stocks I Like Now

Two Oncology Stocks I Like Now

M&A activity should pick up in the biotech space.

Waste Management, Blackstone Group, Xilinx: 'Mad Money' Lightning Round

Waste Management, Blackstone Group, Xilinx: 'Mad Money' Lightning Round

Jim Cramer weighs in on Waste Management, Blackstone Group, Xilinx, Celgene, Nvidia, Exelixis, Moneygram and more.

Trump, Trade and Tariffs: Cramer's 'Mad Money' Recap (Thursday 5/3/18)

Trump, Trade and Tariffs: Cramer's 'Mad Money' Recap (Thursday 5/3/18)

Jim Cramer thinks that, finally, bargain hunters are just saying, "Enough already! It can't be that bad."

Exelixis And Invenra Enter Into Collaboration To Discover And Develop Novel Biologics To Treat Cancer

Exelixis And Invenra Enter Into Collaboration To Discover And Develop Novel Biologics To Treat Cancer

Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a collaboration with Invenra, Inc.

Exelixis Announces First Quarter 2018 Financial Results And Provides Corporate Update

Exelixis Announces First Quarter 2018 Financial Results And Provides Corporate Update

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2018 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.

Exelixis' Partner Ipsen Announces EMA Validation Of The Application For A New Indication For CABOMETYX® (cabozantinib) For Previously Treated Advanced Hepatocellular Carcinoma

Exelixis' Partner Ipsen Announces EMA Validation Of The Application For A New Indication For CABOMETYX® (cabozantinib) For Previously Treated Advanced Hepatocellular Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen received validation of the application for variation to the CABOMETYX ® (cabozantinib) marketing authorization from the European Medicines...

Exelixis' Partner Ipsen Announces Positive CHMP Opinion For CABOMETYX® (cabozantinib) For Previously Untreated Intermediate- Or Poor-Risk Advanced Renal Cell Carcinoma

Exelixis' Partner Ipsen Announces Positive CHMP Opinion For CABOMETYX® (cabozantinib) For Previously Untreated Intermediate- Or Poor-Risk Advanced Renal Cell Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines...

Which Hot Biotech Name Will Be Acquired Next?

Which Hot Biotech Name Will Be Acquired Next?

Your burning biotech questions answered in our latest mailbag.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AXU, INOV, IT, KEYW, QCP, QSR, SHEN Downgrades: AMID, DM, EXEL, GDEN, LCUT, OIS, VJET Initiations: IMOS Read on to get TheStreet Quant Ratings' detailed report:

Bret Jensen's Biotech Mailbag

Bret Jensen's Biotech Mailbag

We'll answer two of the common questions we have received so far in March.

Exelixis Submits U.S. Supplemental New Drug Application For CABOMETYX® (Cabozantinib) For Previously Treated Advanced Hepatocellular Carcinoma

Exelixis Submits U.S. Supplemental New Drug Application For CABOMETYX® (Cabozantinib) For Previously Treated Advanced Hepatocellular Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) today announced it has completed the submission of a supplemental New Drug Application (sNDA) to the U.

Exelixis Announces Webcasts Of Investor Conference Presentations In March

Exelixis Announces Webcasts Of Investor Conference Presentations In March

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Exelixis Announces Collaborator Daiichi Sankyo's Submission Of Regulatory Filing For Esaxerenone (CS-3150) In Japan

Exelixis Announces Collaborator Daiichi Sankyo's Submission Of Regulatory Filing For Esaxerenone (CS-3150) In Japan

Exelixis, Inc. (NASDAQ: EXEL) today announced that its partner Daiichi Sankyo Company, Limited ("Daiichi Sankyo") has submitted its regulatory application for esaxerenone (INN; code name CS-3150) as a treatment for...

Exelixis Announces Fourth Quarter And Full Year 2017 Financial Results And Provides Corporate Update

Exelixis Announces Fourth Quarter And Full Year 2017 Financial Results And Provides Corporate Update

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and full year of 2017 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and...

Exelixis To Present At The RBC Capital Markets Global Healthcare Conference On February 21, 2018

Exelixis To Present At The RBC Capital Markets Global Healthcare Conference On February 21, 2018

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Exelixis Announces Results From A Phase 2 Investigator-Sponsored Trial Of Cabozantinib In The First-Line Treatment Of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

Exelixis Announces Results From A Phase 2 Investigator-Sponsored Trial Of Cabozantinib In The First-Line Treatment Of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) today announced results from a phase 2 investigator-sponsored trial (IST) of cabozantinib for the first-line treatment of metastatic radioiodine (RAI)-refractory differentiated thyroid...

Exelixis To Release Fourth Quarter And Full Year 2017 Financial Results On Monday, February 26, 2018

Exelixis To Release Fourth Quarter And Full Year 2017 Financial Results On Monday, February 26, 2018

Exelixis, Inc. (NASDAQ: EXEL) announced today that its fourth quarter and full year 2017 financial results will be released on Monday, February 26, 2018 after the markets close.

Exelixis Announces Updated Phase 1 Trial Results For Cabozantinib In Combination With Nivolumab With Or Without Ipilimumab In Refractory Genitourinary (GU) Tumors

Exelixis Announces Updated Phase 1 Trial Results For Cabozantinib In Combination With Nivolumab With Or Without Ipilimumab In Refractory Genitourinary (GU) Tumors

Exelixis, Inc. (NASDAQ:EXEL) today announced updated data from expansion cohorts in a phase 1 trial of cabozantinib in combination with either nivolumab or nivolumab plus ipilimumab in patients with refractory...

Exelixis To Present At The Leerink Partners Global Healthcare Conference On February 14

Exelixis To Present At The Leerink Partners Global Healthcare Conference On February 14

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

TheStreet Quant Rating: C+ (Hold)